| Wed, Nov 4, 2009 | | • | [video] Buy Wellpoint
at TheStreet.com (Wed, Nov 4)
| | Tue, Nov 3, 2009 | | • | Cramer Finds Catalyst for Celgene's Stock
at CNBC (Tue, Nov 3)
| | • | Cramer: The 8 Stocks That Control the Market
at CNBC (Tue, Nov 3)
| | • | ViiV vows joint venture will help fight HIV
at FT.com (Tue, Nov 3)
| | • | Cramer's 'Mad Money' Follow-Up: Nov. 3
at TheStreet.com (Tue, Nov 3)
| | • | [$$] High Yielders Get Lost in Rush Back to Risk
at The Wall Street Journal Online (Tue, Nov 3)
| | • | [$$] 'Hope' Trade Still Has Legs
at Barrons.com (Tue, Nov 3)
| | • | [$$] A Boxed-In Market
at RealMoney by TheStreet.com (Tue, Nov 3)
| | • | Amylin Scores a Hat Trick
at Motley Fool (Tue, Nov 3)
| | • | [video] 3 Stocks I Saw on TV
at TheStreet.com (Tue, Nov 3)
| | • | Trading Outlook for Avanir Pharmaceuticals Inc. Issued by InvestorSoup.com
GlobeNewswire (Tue, Nov 3)
| | • | One Sign of a Strong Stock
at Motley Fool (Tue, Nov 3)
| | Mon, Nov 2, 2009 | | • | A Cure for Cancer?
at CNBC (Mon, Nov 2)
| | • | [video] Battling Cancer
at CNBC (Mon, Nov 2)
| | • | Cramer's 'Mad Money' Recap: Bears Blinded by Negativity (Final)
at TheStreet.com (Mon, Nov 2)
| | • | Cramer's 'Mad Money' Recap: Bears Blinded by Negativity (Update 3)
at TheStreet.com (Mon, Nov 2)
| | • | Positive Phase III Data On XIFAXAN Will Drive Transformation Of Small GI Company According To Award Winning Piper Jaffrey Analyst
Wall Street Transcript (Mon, Nov 2)
| | • | CEO Interview: Telik, Inc. - Dr. Michael M. Wick and Cynthia M. Butitta
Wall Street Transcript (Mon, Nov 2)
| | • | Supreme Court Rejects Plavix Patent Challenge
at The Wall Street Journal Online (Mon, Nov 2)
| | • | AMRI receives $750K milestone payment
at bizjournals.com (Mon, Nov 2)
| | • | [$$] Fitz Bits: Steel Yourself for Downside in X
at RealMoney by TheStreet.com (Mon, Nov 2)
| | • | Trading Review for Cell Therapeutics Incorporated Issued by Beacon Equity
GlobeNewswire (Mon, Nov 2)
| | • | Peter Brimelow: Turnaround Letter not for faint of heart
at MarketWatch (Mon, Nov 2)
| | Sat, Oct 31, 2009 | | • | BARACLUDE® (entecavir) Demonstrated Greater Antiviral Efficacy Compared to Adefovir in New Study of Chronic Hepatitis B Patients with Evidence of Decompensated Cirrhosis
Business Wire (Sat, Oct 31)
| | • | Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b Results for PEG-Interferon Lambda in Hepatitis C
Business Wire (Sat, Oct 31)
|
Add BMY News to My Yahoo!:
 
| |
|
0.31% Nasdaq 0.00%
Headlines
